CSL to drop Terumo for Haemonetics in US plasma collection supply deal
CSL Plasma will expand its supply agreement with Haemonetics (HAE) to all 300+ U.S. plasma donation centers, transitioning to the NexSys PCS platform by 2027. The deal ends CSL's partnership with Terumo BCT, which estimates a $610M impact. Haemonetics stock rose 17% to $119 per share.
How this was made
The 30-second read
Why it matters
The announcement triggered a 17% jump in Haemonetics shares, indicating strong market reaction to the contract's scale and revenue implications.
Market read
The deal is a material revenue catalyst for Haemonetics and may reshape competitive dynamics in the plasma collection market.
What to watch
Potential regulatory scrutiny of the expanded contract and the impact of Terumo's impairment charges on its competitive position.
Background
CSL Plasma is expanding its partnership with Haemonetics, replacing Terumo BCT equipment across more than 300 US donation centers.
Ticker impact
Haemonetics announced an expanded supply deal with CSL Plasma, causing its stock to jump about 17% intraday.
likely continued upside as investors price in higher revenue from the expanded deal
The deal adds over 300 sites and follows a previous $117M contract, representing a material revenue boost.
Market effects
Strengthens the plasma collection equipment sector and may pressure peers like Terumo BCT.
Positive for US biotech manufacturing and related supply chains.
Highlights growing demand for plasma products worldwide.
Counterpoint
If the rollout faces operational delays, the stock could face short-term profit taking after the initial surge.
Key entities
- CompanyHaemonetics
US-listed medical device maker providing plasma collection systems.
- CompanyCSL Plasma
Global plasma collection business of CSL Ltd.
